PMC:100324 / 10805-12164 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/100324","sourcedb":"PMC","sourceid":"100324","source_url":"https://www.ncbi.nlm.nih.gov/pmc/100324","text":"Comorbidities\nInformation on the existence of comorbidities was extracted from the claims data using the occurrence of ICD-9 codes associated with comorbid conditions included in the Charlson Index [24]. We also analyzed data for conditions that were not included in that index, but occurred at a high enough frequency to warrant examination as possible comorbidities, in particular hypertension and lipid disorders. We included the following twelve comorbid conditions into our index: diabetes with complications, diabetes w/o complications, hypertension, heart disease, cerebrovascular disease, chronic pulmonary disease, peripheral vascular disease, kidney disease, liver disease, rheumatological diseases, hypothyroidism, and lipid metabolism disorders. Comorbidities were based on physicians' claims with the respective ICD-9 code [14] during the 12-months period preceding the month in which the cancer was diagnosed. The month of diagnosis was excluded to avoid identifying as comorbidities any complications or conditions directly resulting from cancer treatment. Laboratory, radiology, and other diagnostic services were excluded from the comorbidity identification process because tests may have been done to rule out the condition. Each subject was assigned a comorbidity score of 0 (no condition), 1 (one condition), or 2 (two or more conditions).","divisions":[{"label":"Title","span":{"begin":0,"end":13}}],"tracks":[{"project":"2_test","denotations":[{"id":"11879527-1607900-8772353","span":{"begin":199,"end":201},"obj":"1607900"}],"attributes":[{"subj":"11879527-1607900-8772353","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#e9ec93","default":true}]}]}}